Literature DB >> 12693893

When to start therapy for HIV infection: a swinging pendulum in search of data.

H Clifford Lane, James D Neaton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12693893     DOI： 10.7326/0003-4819-138-8-200304150-00018

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  12 in total

1.  Patients' readiness to start highly active antiretroviral treatment for HIV.

Authors:  Hirut T Gebrekristos; Koleka P Mlisana; Quarraisha Abdool Karim
Journal:  BMJ       Date:  2005-10-01

2.  Using mechanistic models to simulate comparative effectiveness trials of therapy and to estimate long-term outcomes in HIV care.

Authors:  Mark S Roberts; Kimberly A Nucifora; R Scott Braithwaite
Journal:  Med Care       Date:  2010-06       Impact factor: 2.983

3.  How HIV treatment could result in effective prevention.

Authors:  Kartik K Venkatesh; Mark N Lurie; Kenneth H Mayer
Journal:  Future Virol       Date:  2010-07       Impact factor: 1.831

4.  Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.

Authors:  Matthew P Fox; Ian M Sanne; Francesca Conradie; Jennifer Zeinecker; Catherine Orrell; Prudence Ive; Mohammed Rassool; Marjorie Dehlinger; Charles van der Horst; James McIntyre; Robin Wood
Journal:  AIDS       Date:  2010-08-24       Impact factor: 4.177

Review 5.  Serious Non-AIDS Conditions in HIV: Benefit of Early ART.

Authors:  Jens D Lundgren; Alvaro H Borges; James D Neaton
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

6.  Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.

Authors:  Abdel G Babiker; Sean Emery; Gerd Fätkenheuer; Fred M Gordin; Birgit Grund; Jens D Lundgren; James D Neaton; Sarah L Pett; Andrew Phillips; Giota Touloumi; Michael J Vjechaj
Journal:  Clin Trials       Date:  2012-04-30       Impact factor: 2.486

7.  Effect of early versus deferred antiretroviral therapy for HIV on survival.

Authors:  Mari M Kitahata; Stephen J Gange; Alison G Abraham; Barry Merriman; Michael S Saag; Amy C Justice; Robert S Hogg; Steven G Deeks; Joseph J Eron; John T Brooks; Sean B Rourke; M John Gill; Ronald J Bosch; Jeffrey N Martin; Marina B Klein; Lisa P Jacobson; Benigno Rodriguez; Timothy R Sterling; Gregory D Kirk; Sonia Napravnik; Anita R Rachlis; Liviana M Calzavara; Michael A Horberg; Michael J Silverberg; Kelly A Gebo; James J Goedert; Constance A Benson; Ann C Collier; Stephen E Van Rompaey; Heidi M Crane; Rosemary G McKaig; Bryan Lau; Aimee M Freeman; Richard D Moore
Journal:  N Engl J Med       Date:  2009-04-01       Impact factor: 91.245

8.  Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.

Authors:  R Scott Braithwaite; Mark S Roberts; Chung Chou H Chang; Matthew Bidwell Goetz; Cynthia L Gibert; Maria C Rodriguez-Barradas; Steven Shechter; Andrew Schaefer; Kimberly Nucifora; Robert Koppenhaver; Amy C Justice
Journal:  Ann Intern Med       Date:  2008-02-05       Impact factor: 25.391

Review 9.  Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.

Authors:  Jonathan A C Sterne; Margaret May; Dominique Costagliola; Frank de Wolf; Andrew N Phillips; Ross Harris; Michele Jönsson Funk; Ronald B Geskus; John Gill; François Dabis; Jose M Miró; Amy C Justice; Bruno Ledergerber; Gerd Fätkenheuer; Robert S Hogg; Antonella D'Arminio Monforte; Michael Saag; Colette Smith; Schlomo Staszewski; Matthias Egger; Stephen R Cole
Journal:  Lancet       Date:  2009-04-08       Impact factor: 79.321

10.  The impact of monitoring HIV patients prior to treatment in resource-poor settings: insights from mathematical modelling.

Authors:  Timothy B Hallett; Simon Gregson; Sabada Dube; Geoff P Garnett
Journal:  PLoS Med       Date:  2008-03-11       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.